New aesthetic device Sylfirm X has debuted in the UK, providing the world’s first FDA-approved dual wave radiofrequency (RF) microneedling treatment.
Novus Medical, the device’s exclusive UK distributor, explains that the technology is designed to address a variety of skin complaints. The device uses Reactive Oxygen Species (ROS)-regulating technology to increase the efficacy of the microneedling, allowing it to boost treatment of rosacea, melasma and redness. According to the company, the dual wave RF is adjustable to treat various skin layers and concerns.
UK aesthetic practitioner and key opinion leader Dr Mahsa Saleki said, ‘’Sylfirm X, dubbed the next generation of RF micro-needling and skin rejuvenation technology, is now available in the UK, supplied by Novus Medical. Unlike conventional RF micro-needling devices, Sylfirm X boasts both continuous wave and pulsed wave technology, enabling it to effectively treat a multitude off skin concerns simultaneously; including hyperpigmentation, skin laxity, facial contouring, sagging skin and stretch marks. In addition, Sylfirm X’s dual wave system is subdivided into eight different modes, allowing practitioner to customise a patient’s treatment to suit their individual skin needs.”
Novus Medical is a UK-based company that specialises in the development, manufacturing and distribution of advanced medical and aesthetic devices. The company states that they offer a range of products designed for various applications, including skin rejuvenation, antiageing treatments and other dermatological and cosmetic procedures.
